Glow-in-the-Dark dye could help breast cancer patients avoid second surgery

NCT ID NCT07140965

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special fluorescent dye and imaging system can help surgeons see and remove all cancer during breast-conserving surgery. The goal is to reduce the chance that cancer cells are left behind, which often requires a second operation. About 175 women with breast cancer will take part. The trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pegulicianine (fluorescent dye) used with the Lumicell Direct Visualization System
What this could lead to: If successful, this approach could help surgeons remove all cancer in one operation, reducing the need for a second surgery and improving outcomes for breast cancer patients.
What could go wrong: This trial is currently suspended, and it is a relatively small, early-stage study focused on safety and feasibility. The technology may not work as hoped or may not reduce second surgeries significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.